BR9812634A - April - uma proteìna com efeitos de crescimento - Google Patents

April - uma proteìna com efeitos de crescimento

Info

Publication number
BR9812634A
BR9812634A BR9812634-2A BR9812634A BR9812634A BR 9812634 A BR9812634 A BR 9812634A BR 9812634 A BR9812634 A BR 9812634A BR 9812634 A BR9812634 A BR 9812634A
Authority
BR
Brazil
Prior art keywords
april
protein
growth effects
growth
effects
Prior art date
Application number
BR9812634-2A
Other languages
English (en)
Portuguese (pt)
Inventor
Jurg Tschopp
Original Assignee
Biogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Inc filed Critical Biogen Inc
Publication of BR9812634A publication Critical patent/BR9812634A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BR9812634-2A 1997-09-12 1998-09-11 April - uma proteìna com efeitos de crescimento BR9812634A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5878697P 1997-09-12 1997-09-12
US7938498P 1998-03-26 1998-03-26
PCT/US1998/019191 WO1999012965A2 (en) 1997-09-12 1998-09-11 April- a novel protein with growth effects

Publications (1)

Publication Number Publication Date
BR9812634A true BR9812634A (pt) 2000-08-22

Family

ID=26738027

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9812634-2A BR9812634A (pt) 1997-09-12 1998-09-11 April - uma proteìna com efeitos de crescimento

Country Status (20)

Country Link
US (3) US20030138884A1 (enExample)
EP (1) EP1027431A2 (enExample)
JP (1) JP2001515712A (enExample)
KR (1) KR100618492B1 (enExample)
CN (1) CN1195849C (enExample)
AU (1) AU759717B2 (enExample)
BR (1) BR9812634A (enExample)
CA (1) CA2303615A1 (enExample)
CZ (1) CZ294615B6 (enExample)
EA (1) EA005411B1 (enExample)
EE (1) EE200000147A (enExample)
HU (1) HUP0004611A3 (enExample)
IL (1) IL134537A0 (enExample)
IS (1) IS5378A (enExample)
NO (1) NO20001242L (enExample)
NZ (1) NZ503850A (enExample)
PL (1) PL339463A1 (enExample)
SK (1) SK3542000A3 (enExample)
TR (1) TR200000669T2 (enExample)
WO (1) WO1999012965A2 (enExample)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6541224B2 (en) 1996-03-14 2003-04-01 Human Genome Sciences, Inc. Tumor necrosis factor delta polypeptides
US7217788B2 (en) 1996-03-14 2007-05-15 Human Genome Sciences, Inc. Human tumor necrosis factor delta polypeptides
WO1999050416A1 (en) * 1997-09-30 1999-10-07 Pharmacia & Upjohn Company Tnf-related death ligand
WO1999026976A1 (en) * 1997-11-26 1999-06-03 Eli Lilly And Company Tnf ligand family gene
US7833529B1 (en) 1999-01-07 2010-11-16 Zymogenetics, Inc. Methods for inhibiting B lymphocyte proliferation with soluble ztnf4 receptor
US20030095967A1 (en) 1999-01-25 2003-05-22 Mackay Fabienne BAFF, inhibitors thereof and their use in the modulation of B-cell response and treatment of autoimmune disorders
ATE515267T1 (de) 1999-01-25 2011-07-15 Biogen Idec Inc Verwendung eines antikörpers gegen wasserlöslich baff zur krebsbehandlung
US20030022233A1 (en) 1999-04-30 2003-01-30 Raymond G. Goodwin Methods of use of the taci/taci-l interaction
EP1210425B2 (en) 1999-08-17 2015-06-17 Biogen MA Inc. Baff receptor (bcma), an immunoregulatory agent
UA74798C2 (uk) 1999-10-06 2006-02-15 Байоджен Айдек Ма Інк. Спосіб лікування раку у ссавця за допомогою поліпептиду, що протидіє взаємодії april з його рецепторами
WO2001025256A2 (en) * 1999-10-06 2001-04-12 University Of Utah Research Foundation Trdl-1-gamma, a novel tumor necrosis-like ligand
EP1259544B1 (en) 2000-02-11 2011-08-24 Biogen Idec MA Inc. Heterologous polypeptide of the tnf family
AU2006201471B2 (en) * 2000-02-16 2009-07-23 Genentech, Inc. Uses of agonists and antagonists to modulate activity of TNF-related molecules
EP1666052B1 (en) * 2000-02-16 2011-06-08 Genentech, Inc. Anti-APRIL monoclonal antibody and its use for the treatment of an immune related disease or cancer
US6774106B2 (en) 2000-05-12 2004-08-10 Amgen Inc. Methods and compositions of matter concerning APRIL/G70, BCMA, BLYS/AGP-3 and TACI
WO2001096528A2 (en) * 2000-06-15 2001-12-20 Human Genome Sciences, Inc. Human tumor necrosis factor delta and epsilon
UA83458C2 (uk) 2000-09-18 2008-07-25 Байоджен Айдек Ма Інк. Виділений поліпептид baff-r (рецептор фактора активації в-клітин сімейства tnf)
GB2370273A (en) * 2000-12-20 2002-06-26 Viaxxel Biotech Gmbh Compounds that affect CD83 expression
MEP21708A (en) 2001-05-24 2010-06-10 Zymogenetics Inc Taci-immunoglobulin fusion proteins
EP1401870A4 (en) 2001-05-24 2006-04-19 Human Genome Sciences ANTIBODIES AGAINST TUMOR NECROSIS FACTOR DELTA (APRIL)
US7399829B2 (en) 2002-01-04 2008-07-15 Xencor, Inc. Variants of RANKL protein
US7381792B2 (en) 2002-01-04 2008-06-03 Xencor, Inc. Variants of RANKL protein
WO2004089982A2 (en) * 2003-01-06 2004-10-21 Xencor April variants and methods thereof
US7553930B2 (en) 2003-01-06 2009-06-30 Xencor, Inc. BAFF variants and methods thereof
WO2004094620A2 (en) 2003-03-28 2004-11-04 Biogen Idec Ma Inc. Truncated baff receptors
US20070249530A1 (en) * 2004-01-29 2007-10-25 Genentech, Inc. Bcma Polypeptides and Uses Thereof
US20050186577A1 (en) 2004-02-20 2005-08-25 Yixin Wang Breast cancer prognostics
WO2005113598A2 (en) * 2004-05-21 2005-12-01 Xencor, Inc. Tnf super family members with altered immunogenicity
AU2005318086B2 (en) 2004-12-23 2011-07-07 Merck Serono Sa BCMA polypeptides and uses thereof
CA2618763A1 (en) 2005-08-09 2007-02-15 Zymogenetics, Inc. Methods for the treatment and prevention of abnormal cell proliferation using taci-fusion molecules
UA93516C2 (ru) 2005-08-09 2011-02-25 Займоджинетикс, Инк. Способы лечения b-клеточных злокачественных образований c помощью слитой молекулы taci-ig
ATE500275T1 (de) * 2005-09-26 2011-03-15 Enzo Life Sciences Els Ag Antikörper gegen april als biomarker zur frühen prognose in lymphompatienten
JP5905184B2 (ja) 2005-10-13 2016-04-20 ヒューマン ジノーム サイエンシーズ， インコーポレイテッドＨｕｍａｎ Ｇｅｎｏｍｅ Ｓｃｉｅｎｃｅｓ， Ｉｎｃ． 自己抗体陽性疾患を有する患者の処置に使用するための方法および組成物
US9726673B2 (en) 2005-11-23 2017-08-08 Genentech, Inc. Methods and compositions related to B cell assays
AR060935A1 (es) 2006-05-15 2008-07-23 Ares Trading Sa Metodos para tratar enfermedades autoinmunes utilizando una molecula de fusion taci- ig
EP4147719A1 (en) 2009-03-02 2023-03-15 Aduro Biotech Holdings, Europe B.V. Antibodies against a proliferating inducing ligand (april)
US8981057B2 (en) * 2010-03-05 2015-03-17 Academisch Medisch Centrum Bij De Universiteit Van Amsterdam B-cell stimulating fusion proteins of an antigen with BAFF or APRIL
WO2011109280A1 (en) 2010-03-05 2011-09-09 Lerner Research Institute Methods and compositions to treat immune-mediated disorders
NL2011406C2 (en) * 2013-09-06 2015-03-10 Bionovion Holding B V Method for obtaining april-binding peptides, process for producing the peptides, april-binding peptides obtainable with said method/process and use of the april-binding peptides.
DK4269430T3 (da) * 2013-09-23 2025-08-18 Regeneron Pharma Ikke-menneskelige dyr, der har et humaniseret signalregulerende proteingen
GB201317929D0 (en) * 2013-10-10 2013-11-27 Ucl Business Plc Chimeric antigen receptor
KR102173297B1 (ko) * 2013-11-19 2020-11-03 리제너론 파마슈티칼스 인코포레이티드 인간화된 증식-유도 리간드 유전자를 가지고 있는 비-인간 동물
NL2014108B1 (en) 2015-01-09 2016-09-30 Aduro Biotech Holdings Europe B V Altered april binding antibodies.
PT3380522T (pt) 2015-11-25 2024-02-14 Visterra Inc Moléculas de anticorpos contra april e suas utilizações
AU2021370895A1 (en) 2020-10-29 2023-06-08 Industrial Polymers and Chemicals, Inc. Air filter with pathogen monitoring and inactivation
CN118678963A (zh) 2021-08-11 2024-09-20 艾克索生物制药有限公司 使用sBCMA变体及其FC融合蛋白减少IgA、IgM和/或IgG的产生的方法
TW202440636A (zh) 2023-03-21 2024-10-16 美商傳記５５有限公司 Ｃｄ１９／ｃｄ３８多特異性抗體
CN118909083A (zh) * 2024-07-30 2024-11-08 江苏省农业科学院 一种猪b细胞增殖诱导配体蛋白及其制备方法和应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5176996A (en) * 1988-12-20 1993-01-05 Baylor College Of Medicine Method for making synthetic oligonucleotides which bind specifically to target sites on duplex DNA molecules, by forming a colinear triplex, the synthetic oligonucleotides and methods of use
US5256775A (en) * 1989-06-05 1993-10-26 Gilead Sciences, Inc. Exonuclease-resistant oligonucleotides
US5264564A (en) * 1989-10-24 1993-11-23 Gilead Sciences Oligonucleotide analogs with novel linkages
AU6166396A (en) * 1995-06-07 1996-12-30 Biogen, Inc. Complexes of modified lymphotoxins as pharmaceutical prepara tions
DE69630710T2 (de) * 1996-03-14 2004-09-23 Human Genome Sciences Inc. Humaner tumornekrosefaktor delta und epsilon
US6509170B1 (en) * 1996-03-14 2003-01-21 Human Genome Sciences, Inc. Polynucleotides encoding human tumor necrosis factor delta
US6171787B1 (en) * 1997-06-26 2001-01-09 Abbott Laboratories Member of the TNF family useful for treatment and diagnosis of disease

Also Published As

Publication number Publication date
CN1195849C (zh) 2005-04-06
EP1027431A2 (en) 2000-08-16
IL134537A0 (en) 2001-04-30
AU759717B2 (en) 2003-04-17
KR100618492B1 (ko) 2006-08-31
PL339463A1 (en) 2000-12-18
NO20001242D0 (no) 2000-03-09
WO1999012965A2 (en) 1999-03-18
AU9316298A (en) 1999-03-29
KR20010023893A (ko) 2001-03-26
CZ2000869A3 (cs) 2000-09-13
TR200000669T2 (tr) 2000-08-21
IS5378A (is) 2000-02-18
CN1270632A (zh) 2000-10-18
CZ294615B6 (cs) 2005-02-16
US20060084148A1 (en) 2006-04-20
WO1999012965A3 (en) 1999-06-03
SK3542000A3 (en) 2000-08-14
NO20001242L (no) 2000-05-11
NZ503850A (en) 2002-12-20
HUP0004611A3 (en) 2002-04-29
US20050112596A1 (en) 2005-05-26
EE200000147A (et) 2001-02-15
EA005411B1 (ru) 2005-02-24
EA200000310A1 (ru) 2000-10-30
CA2303615A1 (en) 1999-03-18
US20030138884A1 (en) 2003-07-24
HUP0004611A2 (hu) 2001-04-28
JP2001515712A (ja) 2001-09-25

Similar Documents

Publication Publication Date Title
BR9812634A (pt) April - uma proteìna com efeitos de crescimento
BR9711046A (pt) Ligando relacionado a fator de necrose de tumor.
EA200000311A1 (ru) Новый белок иммунной системы - кау
DK0725790T3 (da) Substituerede tetra- og pentapeptidinhibitorer af proteinfarnesyltransferase
BR9814956A (pt) Inibidores de benzotiazol da tirosina cinase de proteìna
BR0014214A (pt) Imidazoquinolinas substituìdas com amida
IL151313A0 (en) Lipase containing pharmaceutical compositions
DK0767800T3 (da) Histidin- og homohistidinderivater som inhibitorer af protein farnesyltransferase
DE69939864D1 (de) Ppar-gamma modulatoren
BR9804437A (pt) Compostos para a osteoporose
TR200000927T2 (tr) Prostaglandin agonistleri ve kemik bozukluklarının tedavisi
BR9811099A (pt) Inibidores de urocinase
ATE214610T1 (de) Neuartige pharmazeutische verwendungen von krill- enzymen
DK0971717T3 (da) Cytotoksiske aminosukker- og relaterede sukkerderivater af indolopyrrolocarbazoler
BR0300709A (pt) Sal de perindopril e as composições farmacêuticas contendo o mesmo
BR0316324A (pt) Polipeptìdeos e conjugados de interferon-alfa
PT1032414E (pt) Combinacao de um inibidor da enzima de conversao da angiotensina e de um diuretico para o tratamento de perturbacoes microcirculatorias
MXPA02010458A (es) Peptido modulador del receptor de trombopoyetina.
BR9507437A (pt) Base livre de halofantrina e composições para o tratamento da malária
PT1107793E (pt) Conjugados de dextrano-leptina, composicoes farmaceuticas e processos relacionados
IT1270618B (it) Proteine ad attivita' antitumorale
BR9711540A (pt) Inibidores de protease proteìnico estabilizados e variantes dos mesmos
ID25478A (id) Agonis 5-ht1f
MY127474A (en) Naphthyl compounds, intermediates, compositions, and methods of use
DK0977871T3 (da) Neurotrypsin

Legal Events

Date Code Title Description
PC Transfer

Free format text: APOTECH R&D S.A. (CH)

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements